These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16934353)

  • 1. Patients who have had permanent implant prostate brachytherapy.
    Cousins C; Cosset JM
    Radiother Oncol; 2006 Sep; 80(3):395. PubMed ID: 16934353
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
    Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
    Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
    Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
    Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
    Potters L; Perez CA; Beyer DC; Blasko JC; Forman JD; Hussey DH; Lee WR; Paryani SB; Pollack A; Roach M; Scardino P; Schellhammer P; Leibel S
    Radiology; 2000 Jun; 215 Suppl():1383-400. PubMed ID: 11037554
    [No Abstract]   [Full Text] [Related]  

  • 5. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and dosimetric analysis of 469 prostate cancer patients treated in France in 2005 by permanent implant brachytherapy using the Iodin 125 seeds IsoSeed Bebig: report to the French Economic committee of health products (CEPS)].
    Cosset JM; Gomme S; Peiffert D; Guerif S; Labib A; Hannoun-Lévi JM; Martin P; Quétin P; Nguyen TD; Flam T; Thiounn N; Henni M; Rosenwald JC; Housset M; Pontvert D; Asselain B; Chauveinc L
    Cancer Radiother; 2007 Jun; 11(4):206-13. PubMed ID: 17604675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New 125I dosimetry in prostatic brachytherapy planning.
    Piermattei A
    Rays; 1993; 18(1):58-62. PubMed ID: 8356241
    [No Abstract]   [Full Text] [Related]  

  • 9. Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477).
    Oton CA; Oton F
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):962; author reply 962-3. PubMed ID: 18514795
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment. Variations in International Prostate Symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Sandhu JS
    Urology; 2009 Aug; 74(2):411; author reply 411-2. PubMed ID: 19646629
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on Moerland et al. study of decline of dose coverage between different implant techniques for I125 prostate brachytherapy.
    Al-Qaisieh B
    Radiother Oncol; 2010 Mar; 94(3):386-7; author reply 386. PubMed ID: 20207039
    [No Abstract]   [Full Text] [Related]  

  • 13. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial experiences with iodine-121 implantation in 41 patients with prostatic carcinoma].
    Battermann JJ; Boon TA; Beijert M; de Voogt HJ
    Ned Tijdschr Geneeskd; 1987 Sep; 131(36):1573-6. PubMed ID: 3670438
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
    Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insterstitial brachytherapy of localised prostate cancer using iodine 125 permanent implants].
    Peiffert D
    Cancer Radiother; 2005 Nov; 9(6-7):388-93. PubMed ID: 16223594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura database.
    Orio PF; Merrick GS; Grimm P; Blasko J; Sylvester J; Allen ZA; Butler WM; Chaudhry UU
    Am J Clin Oncol; 2008 Dec; 31(6):523-31. PubMed ID: 19060582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
    Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
    Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate carcinoma: curative radiotherapy.
    Knüfermann H; Wannenmacher M
    Bull Cancer; 1985; 72(6):568-72. PubMed ID: 4092106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.